C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.
NCT ID: NCT04935515
Last Updated: 2021-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2021-04-15
2021-06-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Based on early assessment of inflammatory markers like CRP and clinical signs like persistent high-grade fever, need-based early medical intervention was initiated in home quarantined COVID -19 patients prior to the onset of hypoxia, in order to avoid complications and hospitalization
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Rates of Antimicrobial Use in Febrile Patients With or Without the Use of C-reactive Protein Blood Test
NCT05292508
Impact of the Use of CRP on the Prescription of Antibiotics in General Practitioners
NCT03540706
In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life
NCT04921241
Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19
NCT04534712
CRP for Respiratory Diagnosis in Kyrgyz Pediatric Practice
NCT05195866
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Based on early objective biochemical tests like elevated CRP and clinical signs like persistent high-grade fever on the third or fourth day after onset of symptoms, early medical treatment was initiated prior to onset of hypoxia.
All the 25 patients recovered without any complications and did not require hospitalization.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mild
Patients with mild symptoms and normal CRP.
Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins
Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
Moderate
Patients with mild symptoms and less than 10 fold increase in CRP.
Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins
Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
Oral low dose steroid
Low dose oral methyl prednisolone was added.
Oral anti-coagulant
Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
Severe
Patients with high grade fever persisting even on the third or fourth day after onset of symptoms or 10 fold or more increase in CRP.
Intravenous Antibiotics with Low dose steroid.
Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
Oral anti-coagulant
Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins
Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
Oral low dose steroid
Low dose oral methyl prednisolone was added.
Intravenous Antibiotics with Low dose steroid.
Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
Oral anti-coagulant
Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients consulting online on the 3rd or 4th day after the onset of symptoms.
3. Patients with oxygen saturation 94% and above.
Exclusion Criteria
2. Patients with oxygen saturation less than 94% during the initial presentation.
3. Systemic disease known to increase CRP levels.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UR Anoop Research Group
OTHER
Manimarane Arjunan, MD,DM (Cardiology)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Manimarane Arjunan, MD,DM (Cardiology)
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MANIMARANE ARJUNAN, MD,DM-CARDIO
Role: PRINCIPAL_INVESTIGATOR
UR Anoop Research Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ONLINE
Puducherry, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1/MA/URA/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.